Healthcare -
Biotechnology - NASDAQ - US
$ 8.56
0.473 %
$ 105 M
Market Cap
-2.0
P/E
1. INTRINSIC VALUE
Balance Sheet
Corbus Pharmaceuticals Holdings, Inc.
| Current Assets | 153 M |
| Cash & Short-Term Investments | 149 M |
| Receivables | 0 |
| Other Current Assets | 3.91 M |
| Non-Current Assets | 2.9 M |
| Long-Term Investments | 0 |
| PP&E | 2.52 M |
| Other Non-Current Assets | 385 K |
| Current Liabilities | 11.8 M |
| Accounts Payable | 4.79 M |
| Short-Term Debt | 1.61 M |
| Other Current Liabilities | 5.43 M |
| Non-Current Liabilities | 1.63 M |
| Long-Term Debt | 1.63 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Corbus Pharmaceuticals Holdings, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 48.7 M |
| Operating Income | -48.7 M |
| Other Expenses | -8.51 M |
| Net Income | -40.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Corbus Pharmaceuticals Holdings, Inc.
| Net Income | -40.2 M |
| Depreciation & Amortization | -2.74 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 6.14 M |
| Change in Working Capital | -5.58 M |
| Others | -9.92 M |
| Free Cash Flow | -41.8 M |
Wall Street Analysts Price Targets
Corbus Pharmaceuticals Holdings, Inc.
Wall Street analysts predict an average 1-year price target for CRBP of $59.4 , with forecasts ranging from
a
low of
$35 to a high of $88 .
CRBP Lowest Price Target
Wall Street Target
35 USD
308.88%
CRBP Average Price Target
Wall Street Target
59.4 USD
593.93%
CRBP Highest Price Target
Wall Street Target
88 USD
928.04%
4. DIVIDEND
ANALYSIS
CRBP does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Corbus Pharmaceuticals Holdings, Inc.
Sold
0-3 MONTHS
30.6 K USD 2
3-6 MONTHS
130 K USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
7 M USD 1
9-12 MONTHS
7. News
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab).
globenewswire.com
- 4 weeks ago
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fire side chat at the Piper Sandler 3rd Annual Virtual Obesity Symposium, to be held on June 26, 2025. The event will include presentations by key opinion leaders and fireside chats with companies developing obesity therapeutics. Piper Sandler clients can register for the event through their representative.
globenewswire.com
- 1 month ago
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?
CRBP's pipeline shows promise, especially CRB-701 with early signals of benefit and tolerability, but all programs remain in early clinical stages. The company's financial position is stable for now, with about two years of cash runway, but rising R&D costs could accelerate the need for funding. Market sentiment has become overly negative, valuing the pipeline at essentially zero after a steep drop unrelated to CRBP's own data.
seekingalpha.com
- 1 month ago
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
zacks.com
- 2 months ago
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held June 3-5, 2025 in New York, NY.
globenewswire.com
- 2 months ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.
globenewswire.com
- 2 months ago
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.
zacks.com
- 2 months ago
3 Unconventional Cannabis Stocks to Watch in 2025
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
zacks.com
- 2 months ago
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 764.2% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
- 3 months ago
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the United States under an open IND.
globenewswire.com
- 3 months ago
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 4 months ago
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals (CRBP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
zacks.com
- 4 months ago
8. Profile
Summary
Corbus Pharmaceuticals Holdings, Inc. CRBP
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 105 M
Dividend Yield
0.00%
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Contact
500 River Ridge Drive, Norwood, MA, 02062
https://www.corbuspharma.com
IPO
Date
Oct. 27, 2014
Employees
28
Officers
Dr. Yuval Cohen Ph.D.
Chief Executive Officer & Director
Mr. Sean F. Moran CPA, M.B.A.
Chief Financial Officer
Dr. Ian Hodgson
Chief Operating Officer
Dr. Dominic Smethurst M.A., M.D.
Chief Medical Officer
Ms. Christina Bertsch
Vice President of Human Resources